HbA1c as a Marker of Diabetic Dyslipidemia in Type 2 Diabetic Patients: A Cross Sectional Study.

Abstract

Cardiovascular morbidity & mortality are predominantly seen in diabetic patients with dyslipidemia. But unfortunately, most of the diabetic patients are unaware of their dyslipidemic status. By diagnosing & initiating steps to normalize the levels of circulating lipids, the odds of developing cardiovascular complications and mortality can be decreased. Long term glycemic control can be monitored using glycosylated hemoglobin (HbA1c